Type 2 diabetes mellitus is a progressive disorder, and although oral dual therapy is often initially successful, it is associated with a secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia. Later in the course of the disease, the use of combinations of three oral agents may delay the need for insulin while maintaining glycemic control, thus making aggressive oral treatment more acceptable for many patients.
Combination therapy using oral antidiabetic agents with different mechanisms of action can be highly effective in achieving and maintaining target blood glucose levels.
Type II diabetes mellitus uncontrolled by any dual drug therapy.
Headache, flu like syndrome, nausea, sinusitis and rarely hypoglycemia may occur.
Known hypersensitivity to any of the components.
Trigem 1 is available as a strip of 10 tablets.